Physician profile
Luis Pineiro
NPI 1144263633
$86,283.20
in general payments reported to CMS, 2019-2025
48 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $16K · 2021: $1,626 · 2022: $31K · 2023: $9,282 · 2024: $10K · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,929 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,260.00 |
| Food and Beverage | $5,929.46 |
| Education | $217.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $42,868.22 | 2019-2025 | Ultomiris |
| Kite Pharma, INC. | $28,494.00 | 2019-2025 | Yescarta |
| Apellis Pharmaceuticals, INC. | $2,302.86 | 2022-2023 | Empaveli |
| Rigel Pharmaceuticals, INC. | $1,975.62 | 2022-2024 | Rezlidhia, Tavalisse |
| Seagen INC. | $1,264.94 | 2019-2023 | Adcetris |
| Epizyme, INC. | $1,024.27 | 2020-2021 | |
| Astellas Pharma US INC | $899.11 | 2019-2025 | Xospata |
| Incyte Corporation | $689.09 | 2019-2025 | Monjuvi, Jakafi |
| Genzyme Corporation | $493.66 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $462.92 | 2019-2025 | Livtencity, Ninlaro, Iclusig |
| Abbvie INC. | $444.67 | 2019-2025 | |
| Adc Therapeutics America, INC. | $378.76 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $328.35 | 2020-2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $309.06 | 2022-2024 | |
| Pfizer INC. | $304.54 | 2022-2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $287.89 | 2020-2025 | Reblozyl, Breyanzi |
| Janssen Biotech, INC. | $274.16 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Janssen Scientific Affairs, LLC | $265.66 | 2019-2023 | Darzalex |
| E.R. Squibb & Sons, L.L.C. | $264.86 | 2019-2024 | Onureg |
| Amgen INC. | $231.76 | 2019-2023 | Kyprolis, Blincyto |
| Daiichi Sankyo INC. | $230.39 | 2023-2025 | Vanflyta |
| Sanofi-Aventis U.S. LLC | $221.09 | 2023-2025 | |
| Glaxosmithkline, LLC. | $219.14 | 2021-2025 | Ojjaara, Shingrix, Blenrep |
| Karyopharm Therapeutics INC. | $214.13 | 2020-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $200.94 | 2021-2025 | Prevymis |
| Legend Biotech USA INC. | $184.42 | 2023-2024 | Carvykti |
| Sobi, INC | $179.18 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $161.42 | 2020-2024 | Calquence |
| Novartis Pharmaceuticals Corporation | $160.74 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $159.75 | 2022-2024 | Clonoseq |
| Kadmon Pharmaceuticals LLC | $140.28 | 2021 | |
| Morphosys, US INC. | $113.03 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $83.57 | 2022-2024 | Beleodaq |
| Menarini Silicon Biosystems, INC. | $59.88 | 2023-2024 | Cellsearch |
| Stemline Therapeutics INC. | $59.52 | 2024-2025 | Elzonris |
| Genentech USA, INC. | $59.34 | 2023-2025 | Columvi, Polivy, Lunsumio |
| Syndax Pharmaceuticals, INC. | $51.54 | 2025 | |
| Genmab U.S., INC. | $43.45 | 2023-2024 | Epkinly |
| Recordati_rare_diseases_inc. | $43.20 | 2023-2024 | Sylvant |
| Kyowa Kirin, INC. | $38.88 | 2023-2024 | Poteligeo |
| Autolus INC | $23.19 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $21.46 | 2023 | Somatuline Depot, Onivyde |
| Lilly USA, LLC | $18.39 | 2023 | Jaypirca |
| Invivyd INC | $16.24 | 2025 | Pemgarda |
| Blueprint Medicines Corporation | $15.63 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Pineiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.